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ABSTRACT: Protein−protein interactions (PPIs) are involved in many
of life’s essential biological functions yet are also an underlying cause of
several human diseases, including amyloidosis. The modulation of PPIs
presents opportunities to gain mechanistic insights into amyloid
assembly, particularly through the use of methods which can trap
specific intermediates for detailed study. Such information can also
provide a starting point for drug discovery. Here, we demonstrate that
covalently tethered small molecule fragments can be used to stabilize
specific oligomers during amyloid fibril formation, facilitating the
structural characterization of these assembly intermediates. We exemplify the power of covalent tethering using the naturally
occurring truncated variant (ΔN6) of the human protein β2-microglobulin (β2m), which assembles into amyloid fibrils associated
with dialysis-related amyloidosis. Using this approach, we have trapped tetramers formed by ΔN6 under conditions which would
normally lead to fibril formation and found that the degree of tetramer stabilization depends on the site of the covalent tether and
the nature of the protein−fragment interaction. The covalent protein−ligand linkage enabled structural characterization of these
trapped, off-pathway oligomers using X-ray crystallography and NMR, providing insight into why tetramer stabilization inhibits
amyloid assembly. Our findings highlight the power of “post-translational chemical modification” as a tool to study biological
molecular mechanisms.
■ INTRODUCTION
The regulated self-assembly of proteins into ordered complexes
drives many biological processes, ranging from viral capsid
formation and actin polymerization, to DNA maintenance and
repair.1,2 However, self-assembly can also occur aberrantly as a
result of changes in the concentration,3 environment,4−6
primary sequence,7,8 or post-translational processing9−11 of a
protein. Aberrant assembly events are associated with a range
of disorders, and they can involve polymerization of natively
folded protein molecules,2 as in sickle cell anemia,12 or
aggregation which is accompanied by significant conforma-
tional changes, as exemplified by amyloid diseases.13,14
Understanding the molecular basis and consequences of such
protein−protein interaction (PPI) pathways and identifying
methods for their modulation15−20 therefore have implications
for the treatment of disease,21 as well as in the development of
new biomaterials, where protein self-assembly can be exploited
to yield structures with defined architectures or novel
biomechanical properties.22,23 However, manipulating and
defining the mechanisms of self-assembly is challenging, due
to the transient nature and heterogeneity (in mass and
structure) of oligomeric intermediates.24,25 The use of methods
to trap specific oligomeric complexes can help overcome these
challenges and offers the opportunity to structurally character-
ize otherwise transient intermediates, identify targets for drug
discovery, and develop new scaffolds for protein-based
nanostructures.
Here, we describe the use of disulfide tethering26 to rapidly
explore chemical space and identify “post-translational
chemical modifications”27,28 that stabilize specific PPIs
associated with amyloid assembly. These site-specific, covalent
modifications may act in one of two ways: altering the surface
properties of the protein and/or covalently reinforcing a
noncovalent protein−ligand interaction. Using a naturally
occurring, amyloidogenic variant of β2-microglobulin (β2m)
the ΔN6 variantas a model system, we show that covalently
tethered fragments represent highly effective tools for tuning
oligomer populations and stabilizing particular species in self-
assembly pathways. By combining kinetic analysis with
structural information obtained from NMR and X-ray
crystallography, the covalent modifications identified here
have led to structural and functional insights into the role of
tetramers in ΔN6 amyloid formation.
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Native monomeric β2m has a seven-stranded immunoglo-
bulin fold and forms the noncovalently bound light chain of
the major histocompatibility class I complex.29 Aberrant self-
assembly of β2m molecules into amyloid fibrils
30 is a hallmark
of dialysis-related amyloidosis (DRA).31−33 The amyloidogenic
variant of β2m which is the focus of this paperΔN6is
formed from the wild-type protein by proteolysis of its N-
terminal six amino acids and makes up ∼20−30% of β2m
molecules found in fibrils extracted from DRA patients.34,35
ΔN6 is capable of rapid assembly into amyloid fibrils in vitro at
near-neutral pH, through the association of the dynamically
structured monomers36 into dimers and hexamers that retain a
nativelike fold37 (Figure 1A). Subsequent conformational
rearrangement of these oligomers into cross-β structures
leads to amyloid fibril formation and elongation.38
Recent structural models of ΔN6 dimers and hexamers have
shown that the DE and BC loops of the protein are involved in
both oligomerization interfaces (Figure 1A).37 The same
regions have also been identified at the interface of amyloid-
competent ΔN6−β2m heterodimers,40 β2m−β2m homo-
dimers,41 and inhibitory heterodimers formed between ΔN6
and a nonamyloidogenic β2m ortholog (murine β2m).
40 These
examples implicate the DE and BC loops, and thereby also the
associated β-strands, as mediators of oligomerization, and thus
targeting these regions (e.g., by small molecules) was
anticipated to yield tools for controlling and studying ΔN6
self-assembly. The dynamic nature of ΔN6 monomers36 and
oligomers,37 combined with the lack of an obvious ligand
binding pocket, has thus far hindered the development of small
molecule modulators of amyloid formation (although protein-
based modulators have been identified42). In light of this
challenge, we focused our efforts on the development of
covalent ligands to manipulate ΔN6 self-assembly, based on
the success of such compounds in targeting other challenging
PPIs.43−45
■ RESULTS AND DISCUSSION
Identifying Covalent Ligands for ΔN6 by Disulfide
Tethering. Computational solvent mapping (using the
FTMap server46) was performed against an NMR-derived
Figure 1. (A) Native monomeric ΔN6 (PDB 2XKU36) contains seven antiparallel β-strands (labeled A−G), with a solvent-excluded disulfide bond
between strands B and F (yellow). The monomeric protein is capable of associating into transient, nativelike dimers and hexamers en route to
amyloid fibrils (structures not drawn to scale).37 The conversion of these nativelike oligomers into fibrils requires structural rearrangement of the
existing β-strands38 and further self-assembly. ΔN6 tetramers have been observed, but their structure and role in fibril formation depend on the
solution conditions.37,39 (B) The two most ligandable sites (pink) of ΔN6 identified by computational solvent mapping are located adjacent to the
BC (target site 1) and DE (target site 2) loops. Three residues (S33, S52, and L65; purple) at these two sites were substituted with cysteine in
order to target each pocket using the disulfide tethering strategy (see Figure 2A). The orientation of ΔN6 in the “Target site 1” panel is the same as
for the monomer shown in (A).
Figure 2. (A) Schematic representation of the disulfide tethering method used to compare noncovalent affinities of different fragments for specific
target sites on ΔN6. When using cocktails of fragments, the compound which forms the most favorable noncovalent interactions with the target
protein while tethered by a disulfide bond will produce the most stable (i.e., highest populated) covalent protein−fragment adduct at equilibrium
this is reflected by a higher RZ score. (B) Data from a disulfide tethering screen against three ΔN6 cysteine variants (S33C, S52C, and L65C)
normalized as RZ scores. For fragments which were present in more than one screening cocktail, data are shown as the mean ± one standard
deviation. Each cysteine variant was present at 5 μM and was incubated for 24 h with 25 μM of each disulfide-linked fragment (in cocktails of five
fragments) and 500 μM βME, in 25 mM sodium phosphate, pH 6.2, 2% v/v DMSO. Black circles are shown for fragments which were synthesized
but not included in the screening library due to poor purity.
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conformational ensemble of ΔN636 in order to predict which
regions of the protein are likely to be hot spots for small
molecule binding. The resulting data (Figure S1) highlighted
two pockets adjacent to the DE and BC loops as promising
targets for ligand development (site 1, between the C and D
strands; and site 2, beneath the DE loop; Figure 1B). To
identify possible covalent ligands for these sites, a library of
small molecules was screened using the “disulfide tethering”
method26 (Figure 2A). First developed by Erlanson and co-
workers as a site-directed screening strategy,47 this approach
uses disulfide bonds to covalently trap and assess the
interaction affinity of small molecules (typically fragments)
which have bound noncovalently to the protein of interest.
Libraries of disulfide-functionalized molecules are screened for
their ability to form disulfide bonds with cysteine variants of
the target protein, as small molecules which exhibit favorable
noncovalent interactions near the free, solvent-exposed
cysteine residue will undergo thiol−disulfide exchange more
effectively due to their increased local concentration. The
relative population of different covalent protein−ligand
complexes at equilibrium can therefore be used as a proxy
for the noncovalent affinity of a given fragment for a particular
region of the target protein.
Three single cysteine variants of ΔN6 (S33C, S52C, and
L65C; Figure 1B) were expressed and purified (Figure S2) in
order to monitor small molecule binding at sites 1 and 2 by
using the disulfide tethering approach. A library of 84
symmetrical disulfides (designed with the aid of molecular
docking, as described in the Supporting Information) was
prepared through the use of solid-phase synthesis, and 76 of
these fragments were sufficiently pure for screening purposes
(Figure S3) and were screened against each ΔN6 cysteine
variant in cocktails of five, in the presence of excess reducing
agent (β-mercaptoethanol, βME; Figure S4). The relative
populations of the different protein−fragment adducts were
assessed at 24 h by electrospray ionization mass spectrometry
and normalized as robust Z (RZ) scores48 (Figure 2B; Figures
S5−S7), where higher RZ scores were anticipated to reflect
more favorable protein−fragment interactions (Figure 2A).
Comparison of the distribution of protein−fragment adducts
observed for the three ΔN6 cysteine variants to that of an
unrelated, largely helical control protein, MCL-1, showed that
there was poor correlation between the datasets for S52C−
and L65C−ΔN6 with that for MCL-1 (median r = 0.37;
Figure S6) and therefore that the identity of the protein affects
which protein−fragment adducts dominate at equilibrium. The
higher correlation between the datasets for S33C−ΔN6 and
MCL-1 reflects the similar chemical nature of their binding
pockets (Figure S6). These observations suggest that the
preference of ΔN6 for particular fragments (as shown in
Figure 2B) is a result of specific noncovalent interactions. RZ
scores were therefore used to report on the relative
noncovalent affinities of tethered fragments for a particular
region on the surface of ΔN6.
Covalent Functionalization and Ligand Binding Drive
ΔN6 Tetramerization. To interrogate how covalent
modification of the different regions of ΔN6 affects
aggregation, sedimentation velocity analytical ultracentrifuga-
tion (SV-AUC) was used to assess the oligomeric state of a
series of individual protein−fragment adducts (Figure 3A;
Figures S8−S10). Fragments with a range of RZ scores were
selected for testing with each cysteine variant, so as to
distinguish between changes in oligomeric state which are due
to covalent modification of the protein (i.e., changes observed
for all samples of a given cysteine variant) versus changes
which arise from specific noncovalent protein−ligand inter-
actions (i.e., those observed only for covalently tethered
fragments with high RZ scores).
In the absence of covalent modification, ΔN6 is approx-
imately 50% monomeric under the conditions employed (150
μM protein, pH 6.2, 25 °C), with dimers, tetramers, and
hexamers representing the majority of faster sedimenting
species (Figure S2), consistent with previous reports.37
Tethering of high RZ score fragments to all three ΔN6
cysteine variants was found to increase the population of
tetramers (representative data in Figure 3B,D; see also Figures
S11−S13). Tethering with low RZ score fragments, however,
produced a variety of results, which depended both on the
cysteine variant and the ligand employed.
For L65C−fragment adducts, the area of the tetramer peak
in the continuous sedimentation coefficient (c(s)) distributions
showed a positive correlation with the RZ score of the tethered
Figure 3. (A) Examples of fragments used to form the S52C− and
L65C−fragment adducts studied by SV-AUC. (B−E) SV-AUC data
collected for L65C−fragment adducts (B, C) or S52C−fragment
adducts (D, E). Experiments were performed with 150 μM protein in
25 mM sodium phosphate at pH 6.2, 25 °C. Peaks in the c(s)
distributions were assigned to monomer (m), dimer (d), tetramer (t),
or hexamer (h), based on previous studies37 and predicted
sedimentation coefficients for these oligomers (calculated using the
Svedberg equation49). Tetramer peak areas for a range of L65C−
fragment adducts were found to correlate with the RZ score of the
attached fragment (C). The relationship between fragment RZ score
and tetramer peak area for S52C−fragment adducts was less clear, and
other properties of the fragments may play a role in modulating
tetramer populations (E) (see Figure S14).
Journal of the American Chemical Society pubs.acs.org/JACS Article
https://dx.doi.org/10.1021/jacs.0c10629
J. Am. Chem. Soc. 2020, 142, 20845−20854
20847
fragment (Figure 3C; Figures S13, S14): a covalently attached
fragment with a low RZ score (βME) produced an oligomer
distribution which was similar (albeit not identical) to that of
ΔN6 alone (tetramer peak areas of 5 and 18%, respectively),
while tethered fragments with high RZ scores produced
significantly larger tetramer peaks (e.g., a 45% tetramer peak
area was observed for the adduct between L65C and disulfide
54, named L65C−S54; Figure 3B,C). The only predicted
ligandable pocket that is near residue 65 of ΔN6 is target site 2
(Figure 1B), suggesting that the formation of tetramers by
L65C−fragment adducts is driven by noncovalent binding to
this pocket.
The nature of the relationship between tetramer population
and fragment RZ score for the S52C− and S33C−fragment
adducts was less clear. All S52C−fragment adducts produced
tetramer peak areas of ≥43% (with most between 86 and
95%), regardless of RZ score (Figure 3D,E; Figures S12, S14),
implying that a different property of the fragments was driving
the changes in oligomeric state at this site. Although a limited
range of fragment sizes were used in screening, the observed
tetramer populations for the different S52C−fragment adducts
are consistent with fragment size (and thus the surface
topography of protein−fragment adducts) being a contributing
factor (Figure S14). The S33C−fragment adducts analyzed
were generally polydisperse, with only two samples (of seven
analyzed) producing c(s) distributions which were readily
interpretable (Figure S11): S33C−βME and S33C−S79, the
latter of which showed an increased tetramer peak area (43%)
over the former (16%). These data are insufficient to ascertain
which characteristic (characteristics) of the covalent fragments
influences (influence) the tetramer population of S33C−
fragment adducts, but they show that, as for L65C and S52C,
the addition of specific covalent fragments to S33C can be
used to modulate oligomer distributions.
Tetramer Stabilization Inhibits Amyloid Assembly.
The ability of covalently tethered fragments to generate
defined oligomer populations offered the opportunity to
explore the effect of tetramer stabilization on ΔN6 amyloid
assembly. Protein−fragment adducts with a range of tetramer
populations were added to preformed ΔN6 amyloid fibrils, and
the ability of these samples to elongate the fibril seeds was
analyzed using the fluorescent, fibril-binding dye, thioflavin T
(ThT).50,51 By using this strategy, fibril elongation by each
sample will be templated by seeding to a common fibril
product, irrespective of the covalent ligand, enabling direct
comparison of the initial rates of fibril growth for different
protein−fragment adducts. It should be noted that, under the
conditions employed, spontaneous (i.e., unseeded) fibril
formation does not occur on the time scale of the experiment.
For all three ΔN6 cysteine variants, the observed initial
elongation rates were lower for samples with higher tetramer
populations (Figure 4; Figure S15A,B). The most dramatic
change in fibril elongation was seen for S52C−S54 (86%
tetramer peak area in the c(s) distribution), where the rate of
elongation was reduced more than 30-fold relative to ΔN6
(Figure 4E,F). Global linear regression analysis across all
samples showed that there is a negative correlation (r = −0.78)
between the observed initial fibril elongation rate and tetramer
population, and extrapolation of the linear regression line to
100% tetramer corresponds precisely to an elongation rate of
zero (Figure S15B). Together, these observations indicate that
the tetramers formed by the S33C−, S52C−, and L65C−
fragment adducts lie off-pathway to amyloid fibril formation.
Prediction of elongation rates using kinetic schemes in which
tetramers lie on- or off-pathway to fibrils also supports this
conclusion (Figure S16). The fibril elongation data thus
highlight tetramer stabilization as a strategy to inhibit ΔN6
amyloid formation. In addition, they support a model in which
covalent functionalization and covalent reinforcement of ligand
binding around the DE and BC loops can be used to slow the
progression of seeded amyloid formation by modulating the
stability and population distribution of oligomers.
Structural Characterization of Stabilized Tetramers.
To understand how the tetramers generated by the covalent
modification of ΔN6 are structurally related to the previously
characterized ΔN6 dimers and hexamers,37 as well as how and
why covalent modification around the DE and BC loops leads
to tetramerization, X-ray crystallography and solution-state
NMR structural studies were performed.
S52C−S54 was found to crystallize as a ring-shaped tetramer
with a solvent-accessible central cavity, formed from two
asymmetric units each containing two ΔN6 molecules in an
antiparallel orientation (Figure 5A−C; Table S1). As seen for
Figure 4. Change in ThT fluorescence over time for various protein−
fragment adducts (150 μM) in the presence of ΔN6 fibril seeds (15
μM monomer equivalents) shows that the ability of samples to
elongate fibrils depends on the tetramer population. ThT fluorescence
curves in (A), (C), and (E) are shown as the median curve, with the
highest and lowest values shaded in gray (n = 3). The relationship
between the initial elongation rates calculated from these curves and
the tetramer peak areas from the corresponding c(s) distributions are
shown in (B), (D), and (F). Error bars (standard deviation) are
shown for all data points (mean values) in (B), (D), and (F)those
error bars that are not visible are smaller than the displayed data
point. Additional ThT fluorescence curves associated with (B) which
were not shown in (A) (i.e., the white circles in (B)) are shown in
Figure S15A. All experiments were performed under quiescent
conditions in 25 mM sodium phosphate at pH 6.2, 25 °C. Elongation
rates for unliganded ΔN6 are shown by black crosses in (B), (D), and
(F).
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the on-pathway ΔN6 dimer and hexamer,37 the protein
subunits in the crystallized tetramer are highly nativelike, but
notably with perturbations to the DE and BC loops as well as a
shift of the D strand from a β-bulge to a straight β-strand
(Figure 5D; Figure S17A). These structural changes appear to
be linked to each other and to tetramerization: straightening of
the D strand allows for protein−protein interactions to occur
via β-sheet augmentation, forming one of the two interaction
interfaces in the tetramer (Figure 5B), and additionally results
in a rearrangement of phenylalanine residues at the top of the
D, E, and B strands (Phe56, Phe62, and Phe30, respectively)
which is accommodated by rearrangement of the BC loop
(Figure S17B). This movement of residues around the BC and
DE loops allows several key protein−protein contacts to be
made within the second interaction interface, which occurs
through a face-to-face, antiparallel interaction of the ABED β-
sheets (Figure 5C; Figure S17C).
Clear electron density indicated the presence of four
covalently bound −S54 fragments within the central cavity
of the tetramer (Figure 5A; bottom structure) which make
intrasubunit and/or intersubunit contacts with the site 2
pocket of surrounding protein subunits (Figure 5E; Figure
S17C). The protein−ligand interactions with the strongest
electron density, and which are therefore the interactions
which presumably contribute most to the stabilization of the
tetramer, involve π stacking between two Tyr26 residues
within the ABED sheet interface and the bicyclic ring system of
a fragment 54 molecule (gray ligand in Figure 5E)this
arrangement is seen for two of the four fragments in a tetramer.
These protein−ligand interactions may additionally stabilize
the straight conformation of the D strand: residue 52 lies too
far from Tyr26 in the monomeric ΔN6 structure for fragment
54 to interact with Tyr26, and it thus appears that this
protein−ligand interaction can only form when the D strand is
Figure 5. (A−C) Crystal structure of the S52C−S54 tetramer (diffracted to 2.4 Å; PDB 7AFV), formed from two asymmetric units: subunits 1a/
1b (gray/pale blue) and subunits 2a/2b (pale green/dark green). Protein subunits interact via two interfaces: the D strand interface (B) and the
ABED sheet interface (C). Four copies of the covalent −S54 fragment (shown as spheres in A and C) are present in this complex and lie within the
ABED sheet interface, in a central solvent-accessible cavity (C). (D) Per-residue, pairwise RMSD values for the S52C−S54 tetramer crystal
structure (subunit 1a/2a) compared with the monomeric ΔN6 NMR ensemble (30 structures; PDB 2XKU36), reported for all non-hydrogen
atoms as the mean RMSD (±standard deviation). Residues which are ≤6 Å from another protein subunit or a −S54 fragment within the S52C−
S54 tetramer structure are additionally highlighted by green or purple bars, respectively. The locations of the β-strands in the S52C−S54 tetramer
crystal structure are shown above the plot. (E) Each −S54 fragment can bind in one of two binding sites around the site 2 pocket: by π stacking
between two Tyr26 residues within the ABED sheet interface (top) or by π stacking against Tyr67 (bottom). The 2Fo−Fc electron density map
(contoured at 1.1σ) is shown in cyan for the displayed amino acid side chains and organic molecules. (F) Combined 1H−15N chemical shift
differences between S52C−S54 and L65C−βME HMQC NMR spectrathese samples had tetramer peak areas of 86 and 5%, respectively, in their
c(s) distributions. Residues which were not visible (or could not be confidently assigned based on comparison with previous ΔN6 assignments36)
for either sample are shown as black circles. Residues which were visible for L65C−βME but were broadened beyond detection for S52C−S54 are
shown by purple bars. Resonances which were visible in both spectra are colored according to the magnitude of the chemical shift perturbation
(CSP) relative to the standard deviation of the dataset (σ): CSP ≥ 2σ, red; σ ≤ CSP < 2σ, yellow; CSP < σ, gray. Four main regions (labeled 1−4)
show either significant changes in the position of 1H−15N resonances or complete loss of these resonances in samples with higher tetramer
populations (see also Figure S21).
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straight (Figure S17D). Therefore, while no direct protein−
ligand contacts occur with either the DE or BC loops, contacts
with the associated β-strands appear to have driven conforma-
tional changes in these regions, and together the observed
structural changes have altered the ΔN6 self-assembly
landscape in favor of the tetramer. The electron density
associated with the remaining two fragments in the tetramer is
not as well-defined as for those intercalated between Tyr26
residues, but it suggests a binding mode whereby the fragments
can form intrasubunit π−π interactions with Tyr67 residues
(Figure 5E, pale blue ligand).
1H−15N heteronuclear multiple quantum coherence
(HMQC) NMR spectra and 15N-relaxation measurements
acquired for various S52C− and L65C−fragment adducts were
consistent with the tetramer observed within the S52C−S54
crystal lattice, implying that this crystal structure reflects the
nature of these off-pathway ΔN6 tetramers in solution (Figures
S18−S21). Comparison of the chemical shifts and intensities
of 1H−15N backbone amide resonances between samples with
higher tetramer populations (e.g., S52C−S54 and L65C−S54)
and those with lower tetramer populations (e.g., ΔN6,
L65C−βME) showed differences across four regions of
primary sequence (labeled 1−4 in Figure 5F and Figure
S21). Regions 1−3 contain residues that either make up the
tetramer interaction interfaces and/or have shifted significantly
(≥4 Å root-mean-square deviation, RMSD) in the crystal
structure relative to monomeric ΔN6 (Figure 5D). While
region 4 does not undergo any structural changes itself in the
crystal structure, it is adjacent to the BC loop, and hence
residues in region 4 will experience a change in chemical
environment upon tetramerization (Figure 5D).
In addition to the NMR data supporting the relevance of the
S52C−S54 crystal structure to oligomerization in solution, the
NMR data also indicate that the tetramers formed by the
S52C− and L65C−fragment adducts are structurally similar.
The ability of S52C− and L65C−fragment adducts to adopt
similar tetrameric species can be rationalized in the context of
the crystal structure. D strand straightening results in residues
52 and 65 now lying adjacent to one another (Figure S17A,
inset), so we anticipate that fragments tethered to the L65C
variant of ΔN6 can access the same binding pockets which
−S54 is observed to occupy in the S52C−S54 crystal structure.
Structural Similarities of Off-Pathway ΔN6 Tetramers
with Full-Length β2m Oligomers. While similar regions of
ΔN6 are involved in the formation of the off-pathway tetramer
and the previously identified on-pathway dimers/hexamers
(which were characterized under conditions similar to those
employed here),37 the PPIs themselves are significantly
different and mutually exclusive (Figure S22A). This
observation rationalizes the off-pathway behavior of the
tetramer, as it would need to completely dissociate to form
the on-pathway hexamer. However, although the tetramer is
different from previously identified ΔN6 oligomers,37,42,52 its
interfaces resemble those observed in oligomers of the full-
length β2m protein.
53−56 The most striking similarities are
those with a crystallographic tetramer formed by the P32A
variant (PDB 2F8O;53 Figure S22B,C). P32A β2m is largely
monomeric in solution53 (in the absence of divalent copper57),
but at the high concentrations within the crystal lattice the
protein molecules can interact via the same D strand and
ABED interfaces shown in Figure 5 (Figure S22B). Although
the solution relevance of the crystallographic P32A tetramer
was not shown, the NMR data obtained for S52C−S54
confirm that this arrangement of protomers is possible in
solution and stable in the presence of suitable ligands.
While the crystallographic P32A β2m tetramer possesses the
same straight D strand as the S52C−S54 ΔN6 tetramer, other
β2m oligomers for which high-resolution structural information
is available lack straight D strands and instead involve DE and
BC loop-mediated PPIs.54−56 Since these oligomers which lack
straight D strands have been shown (or proposed) to be on-
pathway species, we hypothesize that formation of an eight-
stranded ABED−DEBA β-sheet is an off-pathway PPI which
can be driven by ligand binding across the ABED sheet (as
seen for ΔN6 S52C−S54) or modulation of the BC loop (as
for β2m P32A).
■ CONCLUSIONS
Covalent small molecules are becoming increasingly attractive
tools to modulate specific protein−protein interac-
tions,44,45,58−60 to interrogate the role of different proteins in
biological processes,45,58,61−63 and to facilitate structural
studies of challenging targets.43,64 The results presented here
expand this covalent chemical tool approach, highlighting its
power to facilitate analysis of the structure and the role of
specific oligomers in self-assembly pathways. We have
demonstrated that covalently reinforced protein−ligand
interactions65,66 can be used to manipulate heterogeneous
and dynamic PPIs, exemplified by those formed in the initial
stages of amyloid formation, which are notoriously difficult to
target selectively when purely noncovalent approaches are
used.67 Specifically, covalent ligands identified by disulfide
tethering allowed a transient off-pathway tetramer (as shown
by kinetic data and models) formed by the amyloidogenic
ΔN6 variant of β2m to be trapped and characterized in atomic
detail for the first time. These results highlight the power of the
chemical modification of proteins as a general strategy to
manipulate complex self-assembling systems and to drive the
formation of defined oligomers for detailed study.
■ EXPERIMENTAL SECTION
Safety. No unexpected, new, and/or significant hazards or risks
were associated with this research.
Disulfide Tethering Screening. Screening cocktails were
prepared by combining five disulfide-linked fragments (1.25 mM
each; all present as symmetrical disulfides) in the presence of βME
(25 mM) in DMSO. These initial cocktail mixtures were incubated at
ambient temperature (∼18 °C) for 12 h to allow the formation of
mixed disulfides with βME (which generally had improved aqueous
solubility over the symmetrical disulfides).
Screening cocktails were diluted further into each ΔN6 cysteine
variant (5 μM protein, with 25 μM each disulfide, 500 μM βME, 2%
v/v DMSO) in 25 mM sodium phosphate at either pH 6.2 (main text
data) or pH 8.0 (Supporting Information), and the resulting screening
mixtures were incubated at ambient temperature. The distribution of
covalent protein−fragment adducts over time was analyzed by a
Bruker maXis Impact QTOF mass spectrometer, with an electrospray
ionization source. Samples (1 μL injections) were desalted prior to
mass spectrometry by an in-line Dionex UltiMate 3000 liquid
chromatography system (Thermo Scientific), equipped with an Aeris
Widepore C4 column (Phenomenex), running a gradient between
water and acetonitrile, both supplemented with 0.1% formic acid.
MCL-1 (residues 172−327; purified as described previously68) was
screened using the same procedure, but in 25 mM sodium phosphate,
pH 7.4.
Mass spectra were deconvoluted with the use of a maximum
entropy algorithm (DataAnalysis, Bruker). For each protein−fragment
adduct in each cocktail, the intensity of the deconvoluted peak at 24 h
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was measured relative to the protein−βME adduct peak. These
relative intensities were then converted to RZ scores.48 The RZ score









where xi is the relative intensity of the protein−fragment adduct peak
for fragment i and xall is a list of relative peak intensities for all
protein−fragment adducts in that dataset (i.e., for a given cysteine
variant at a given pH). In all cases, peak intensities were measured
relative to the βME adduct. The medium absolute deviation (MAD)69
is defined as
= | − |x x xMAD( ) 1.4826 median( median( ) )iall all (2)
RZ scores for the disulfide analogue of βME could not be
determined by this method, due to the presence of βME as a reducing
agent in all screening mixtures. Instead, its RZ score was estimated
through competition experiments, as shown in Figure S7.
Sedimentation Velocity Analytical Ultracentrifugation.
Experiments were carried out at 48 000 rpm, 25 °C, with an An50-
Ti rotor in a Beckman Coulter Optima XL-I ultracentrifuge. Samples
and reference buffer (400 μL) were loaded into 12 mm aluminum
centerpieces, with sapphire windows. Samples were thermally
equilibrated for 2−3 h at 0 rpm and were subsequently analyzed
using the interference detection system at a protein concentration of
150 μM in 25 mM sodium phosphate, pH 6.2. All samples had been
exhaustively dialyzed in this buffer prior to loading, and the dialysate
was used as the reference buffer.
Data were analyzed in SEDFIT (version 12.44)70 with a
continuous c(s) distribution model and with a maximum entropy
regularization confidence interval of 0.95. Values for the partial
specific volume (ν)̅ of ΔN6, buffer viscosity (η), and buffer density
(ρ) were all calculated with SEDNTERP71 (ν ̅ = 0.72832 mL/g; η =
0.00898 P and ρ = 0.99954 g/mL for 25 mM sodium phosphate, pH
6.2). The final fitting was performed with the Levenberg−Marquardt
algorithm, although initial fitting was performed with both the
Simplex and Levenberg−Marquardt algorithms. For c(s) distributions
with significant peak broadening or overlap, further processing was
subsequently performed to permit baseline resolution of these peaks:
multiple Gaussian functions were fit to the initial c(s) distribution
(using the curve_fit function from SciPy.optimize), and then the
positions of these best fit Gaussians were used in SEDFIT as Bayesian
prior expectations72 (modeled again as Gaussians, located at the best
fit positions identified by curve_fit, with widths set to 0.2 and
amplitudes set to 0.1). Refitting the data with the Levenberg−
Marquardt algorithm led to improved or equally good root-mean-
square deviations (compared to the original c(s) distribution) for all
datasets to which this processing method had been applied,
confirming the validity of this approach.
Peaks in the c(s) distributions were assigned to specific oligomers
based on comparison to published ΔN6 SV-AUC data37 and
predicted sedimentation coefficients for these oligomers. Predicted
sedimentation coefficients were calculated with the Svedberg
equation49 at a range of possible frictional ratios, so as to estimate
the range of possible sedimentation coefficients which could describe
a particle of a given molecular weight.
Thioflavin T Aggregation Assays. Protein−fragment adducts
(150 μM) were incubated in 25 mM sodium phosphate, pH 6.2, with
10 μM ThT, in the presence or absence of 15 μM (monomer
equivalent) fibril seeds prepared from ΔN6, in 96-well untreated half-
area plates (Corning; 100 μL sample per well). In the same plate, 15
μM (monomer equivalent) fibril seeds were incubated alone in 25
mM sodium phosphate, pH 6.2. Details concerning the preparation of
fibril seeds can be found in the Supporting Information.
Fibril elongation was allowed to occur quiescently, with brief
agitation (10 s at 600 rpm) only occurring prior to each reading
(every 12 min). Experiments were performed for 24 h at 25 °C in a
FLUOstar OPTIMA plate reader (BMG Labtech), exciting ThT at
444 nm and measuring its fluorescence emission intensity at 480 nm.
Data were processed by subtracting two datasets from each seeded
dataset to remove changes in ThT fluorescence which had occurred
independently of fibril elongation: (a) data obtained from the same
protein−fragment adduct in the absence of fibril seeds; (b) data
obtained for fibril seeds alone in buffer. The absence of fibrillar
aggregates in the unseeded samples after 24 h was confirmed by
negative-stain electron microscopy (see Supporting Information).
Initial elongation rates from the processed seeded datasets were
measured by fitting a straight line to the first 3 h of data and
determining the gradient.
Protein Crystallography and Data Processing. A stock
solution of S52C−S54 was prepared by incubation of S52C (1.5
mM) and the symmetrical disulfide of fragment 54 (Di-S54; 1.5 mM)
in 25 mM sodium phosphate, pH 8.0, 725 μM βME, 20% v/v DMSO,
for 40 h at room temperature, before exhaustive dialysis against 25
mM sodium phosphate, pH 6.2, at 4 °C, using dialysis tubes with a 3.5
kDa molecular weight cutoff (Generon). The concentration of the
dialyzed sample was determined through a bicinchoninic acid (BCA)
assay.73 Crystals were grown by mixing 0.2 μL of the protein−
fragment complex (1.1 mM) and 0.1 μL of the crystallization solution
in hanging drop plates at 293 K. The crystallization solution (39 mM
bicine, 61 mM Tris, pH 8.5, 7.8% w/v PEG 3350, 7.8% w/v PEG
1000, 7.8% v/v 2-methyl-2,4-pentanediol, and 6.7 mM each of 1,6-
hexanediol, 1-butanol, 1,2-propanediol, 2-propanol, 1,4-butanediol,
and 1,3-propanediol) was prepared from Morpheus Buffer System 3 at
pH 8.5, Morpheus Precipitant Mix 4, and Morpheus Alcohols Mix (all
from Molecular Dimensions). After 2 weeks, crystals were fished and
flash-frozen in liquid nitrogen. The diffraction data were collected at
0.9795 Å, with 0.025 s exposition and 0.15° oscillation, for a total of
2400 images on beamline I24 at Diamond Light Source (U.K.). The
data were processed using the xia274 bundle, with DIALS75 for
integration and using Pointless/Aimless76,77 for scaling and merging.
The data were processed using CC1/2 and completeness as cutoff
criteria.78 The structure of S52C−S54 was solved by molecular
replacement, using full-length β2m (PDB 5CS7
79) with the first six
amino acids removed as the search model in PHASER.80 COOT81
and REFMAC582 were used for refinement. Parameterization of
Cys−S54 (as a non-natural amino acid) was carried out in XPLOR-
NIH,83 followed by refinement of its structure using the
fixupCovalentGeometry function while satisfying the electron density.
The quality of the final structure was assessed with MolProbity.84
Data collection and refinement statistics are shown in Table S1.
Figures were prepared using PyMOL (version 2.4, Schrödinger).
Protein NMR. All spectra were acquired by using a 750 MHz
Bruker Avance III HD spectrometer equipped with a TCI cryoprobe,
at a protein concentration of 150 μM in 25 mM sodium phosphate,
pH 6.2, at 25 °C. 1H−15N SOFAST HMQC spectra were processed
with the use of NMRPipe,85 and calculation of peak intensities was
performed in CcpNmr Analysis (version 2.4).86 1H−15N peaks were
assigned to specific backbone resonances for each protein−fragment
adduct (L65C−βME, L65C−S54, S52C−βME, and S52C−S54) by
comparison to existing ΔN6 assignments,36 only considering peaks
with intensities at least 3-fold greater than the spectral noise.
Backbone chemical shift perturbations (CSPs) between samples were
calculated with eq 3:





where ΔδHN and ΔδN represent the difference in peak position in the
direct and indirect dimensions, respectively.
L65C−βME and L65C−S54 T2 experiments were performed by
acquiring a series of sensitivity-enhanced 1H−15N heteronuclear single
quantum coherence (HSQC) spectra in an interleaved fashion at a
range of delay times (0.017−0.136 ms for L65C−βME, 0.017−0.119
ms for L65C−S54). Peak intensities (I) were extracted from each
spectrum with the series.tab NMRPipe module, and per-residue 15N
relaxation rates (R2) were calculated by fitting the peak intensity at
different delay times (t) to a two-parameter exponential function (eq
4).
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= − −I ae R t2 (4)
For S52C−βME and S52C−S54, sensitivity limitations did not
permit the determination of 15N R2 rates on a per-residue basis.
Instead, the first increment of the standard T2 experiment at each
delay time (0.017−0.102 ms for S52C−βME, 0.017−0.085 ms
S52C−S54) was used to determine the R2 rate of the whole amide
region (7.6−9.2 ppm). Mean 15N R2 rates for the whole amide region
were calculated in the same way for ΔN6 (0.017−0.085 ms) and the
two L65C adducts (L65C−βME and L65C−S54, using the same
datasets acquired for determining per-residue 15N R2 rates).
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Skoŕa, L.; Jahnke, W.; Brunsveld, L.; Arkin, M. R.; Ottmann, C. Site-
directed fragment-based screening for the discovery of protein-protein
interaction stabilizers. J. Am. Chem. Soc. 2019, 141, 3524−3531.
(45) Lee, S.; Wales, T. E.; Escudero, S.; Cohen, D. T.; Luccarelli, J.;
Gallagher, C. G.; Cohen, N. A.; Huhn, A. J.; Bird, G. H.; Engen, J. R.;
Walensky, L. D. Allosteric inhibition of antiapoptotic MCL-1. Nat.
Struct. Mol. Biol. 2016, 23, 600−607.
(46) Kozakov, D.; Grove, L. E.; Hall, D. R.; Bohnuud, T.; Mottarella,
S. E.; Luo, L.; Xia, B.; Beglov, D.; Vajda, S. The FTMap family of web
servers for determining and characterizing ligand-binding hot spots of
proteins. Nat. Protoc. 2015, 10, 733−755.
Journal of the American Chemical Society pubs.acs.org/JACS Article
https://dx.doi.org/10.1021/jacs.0c10629
J. Am. Chem. Soc. 2020, 142, 20845−20854
20853
(47) Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.;
Stroud, R. M.; Gordon, E. M.; Wells, J. A. Site-directed ligand
discovery. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 9367−9372.
(48) Goktug, A. N.; Chai, S. C.; Chen, T. Data analysis approaches
in high throughput screening. In Drug Discovery; IntechOpen: 2013;
pp 201−226.
(49) Svedberg, T.; Pedersen, K. O. The Ultracentrifuge; Oxford
University Press: Oxford, U.K., 1940.
(50) Xue, C.; Lin, T. Y.; Chang, D.; Guo, Z. Thioflavin T as an
amyloid dye: fibril quantification, optimal concentration and effect on
aggregation. R. Soc. Open Sci. 2017, 4, 160696.
(51) Biancalana, M.; Koide, S. Molecular mechanism of Thioflavin-T
binding to amyloid fibrils. Biochim. Biophys. Acta, Proteins Proteomics
2010, 1804, 1405−1412.
(52) Hall, D.; Zhao, R.; So, M.; Adachi, M.; Rivas, G.; Carver, J. A.;
Goto, Y. Recognizing and analyzing variability in amyloid formation
kinetics: Simulation and statistical methods. Anal. Biochem. 2016, 510,
56−71.
(53) Eakin, C. M.; Berman, A. J.; Miranker, A. D. A native to
amyloidogenic transition regulated by a backbone trigger. Nat. Struct.
Mol. Biol. 2006, 13, 202−208.
(54) Calabrese, M. F.; Eakin, C. M.; Wang, J. M.; Miranker, A. D. A
regulatable switch mediates self-association in an immunoglobulin
fold. Nat. Struct. Mol. Biol. 2008, 15, 965−971.
(55) Colombo, M.; De Rosa, M.; Bellotti, V.; Ricagno, S.; Bolognesi,
M. A recurrent D-strand association interface is observed in β-2
microglobulin oligomers. FEBS J. 2012, 279, 1131−1143.
(56) Halabelian, L.; Relini, A.; Barbiroli, A.; Penco, A.; Bolognesi,
M.; Ricagno, S. A covalent homodimer probing early oligomers along
amyloid aggregation. Sci. Rep. 2015, 5, 14651.
(57) Blaho, D. V.; Miranker, A. D. Delineating the conformational
elements responsible for Cu 2+-induced oligomerization of β-2
microglobulin. Biochemistry 2009, 48, 6610−6617.
(58) Wang, N.; Lodge, J. M.; Fierke, C. A.; Mapp, A. K. Dissecting
allosteric effects of activator-coactivator complexes using a covalent
small molecule ligand. Proc. Natl. Acad. Sci. U. S. A. 2014, 111,
12061−12066.
(59) Ruiz, J.; Boehringer, R.; Grogg, M.; Raya, J.; Schirer, A.;
Crucifix, C.; Hellwig, P.; Schultz, P.; Torbeev, V. Covalent tethering
and residues with bulky hydrophobic side chains enable self-assembly
of distinct amyloid structures. ChemBioChem 2016, 17, 2274−2285.
(60) Cardoso, R.; Love, R.; Nilsson, C. L.; Bergqvist, S.; Nowlin, D.;
Yan, J.; Liu, K. K.-C.; Zhu, J.; Chen, P.; Deng, Y.-L.; Dyson, H. J.;
Greig, M. J.; Brooun, A. Identification of Cys255 in HIF-1α as a novel
site for development of covalent inhibitors of HIF-1α/ARNT PasB
domain protein-protein interaction. Protein Sci. 2012, 21, 1885−1896.
(61) Backus, K. M.; Correia, B. E.; Lum, K. M.; Forli, S.; Horning, B.
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